Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2001

View Archived Issues

BAIPs with broad-spectrum anti-HIV activity available for licensing from NIH

Combination of PDE4 and PDE3 inhibitors for Th1-mediated autoimmune diseases

Johnson & Johnson/Alza complete merger

EntreMed and Aventis establish collaborative agreement for phase II prostate cancer trial

Pivotal data reported for Xanelim in psoriasis

Modulation of mitochondrial metabolism as a novel treatment strategy for type 2 diabetes

Potent and selective glucagon receptor antagonist as potential new therapy for type 2 diabetes

Genelabs' NDA for Aslera deemed unapprovable by FDA

Maxia designs molecule with antidiabetic and antidyslipidemic effects

Vion's sulfonylhydrazine prodrug enters phase I evaluation

TBC-1269 enters clinical evaluation as inhaled therapy for asthma

Cellegy files NDA for Anogesic; completes enrollment in second phase III trial

Novuspharma's IND for BBR-2778 accepted by FDA

Selective activation of pancreatic beta-cell K(ATP) channel achieved by diazoxide analogue

Symbollon announces plans for phase III IoGen trials; completes name change

Health Canada approves Levulan Kerastick

ADA news: Telik designs orally active insulin receptor tyrosine kinase activator

Versicor initiates phase II study of novel antifungal agent for invasive candidiasis/candidemia

Positive phase I results reported for Active Biotech's TTS

Novel class of therapeutics for type 2 diabetes: small-molecule glucokinase activators

Vasogen completes patient enrollment in congestive heart failure trial

Inhibitors of beta-amyloid peptide production or release discovered at Lilly

New Aventis compounds useful as anticoagulants for thrombotic disorders

Japanese pharmaceutical company presents new hypoglycemic agents

Stable GLP-1 analogue with enhanced in vivo efficacy: BIM-51077

Antiviral agents active against HSV-1 patented by Toagosei

Sankyo designs dihydroquinoline ileal bile acid transport inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.